ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1762

Endogenous IL-22 Regulates Th1 Responses and Plays a Pathogenic Role After the Onset of Arthritis

Shivali Justa1, Xiaoqun Zhou2 and Sujata Sarkar3, 1Rheumatology & Arizona Arthritis Center, University of Arizona, Tucson, AZ, 2Rheumatology, University of Arizona, Tucson, AZ, 3Rheumatology and Arizona Arthritis Center, University of Arizona, Tucson, AZ

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cytokines and inflammation

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to autoimmune inflammation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

IL-22,belongs to the IL-10 family of cytokines and is primarily produced by CD4 T, NK and LTi cells. IL-22 plays a dual role depending on the context of the disease model under study, it is protective in inflammatory bowel disease, hepatitis, myocarditis, ulcerative colitis and pathogenic in psoriasis. IL-22 knock-out mice have a reduced incidence of arthritis, while neutralization of IL-22 after onset of arthritis in IL-1 receptor antagonist knock-out mice had limited effect on joint inflammation, additionally, administration of IL-22 prior to onset of joint inflammation is associated with reduced arthritis. These findings are suggestive of a nuanced role of IL-22 in the regulation of inflammation.

Methods: CIA was induced in DBA1 mice following immunization with collagen and complete Freund’s adjuvant. Arthritic mice with clinical scores of   ≥ 1 and with arthritis duration of 4 days were randomized to receive anti-IL-22 or RatIgG antibody and disease progression was assessed by clinical scoring and histopathology. IL-22, IL-17 and IFN-g responses were measured by ELISA and flowcytometry. Anti-collagen antibodies were analyzed by ELISA. Expression of IL-22R1 in CD4T, CD19+ and CD11c+ cells was elucidated by flowcytometry and real time PCR

Results:

There was a significant expansion of collagen specific IL-22 responses during arthritis and IL-22 producing cells were discrete from IL-17 or IFN-g producing cells. Neutralization of IL-22 after onset of joint inflammation resulted in significantly reduced severity of arthritis and was accompanied by increase in collagen specific IFN-g responses, a modest reduction of anti-collagen IgG2a antibodies, and unaltered Th17 or IL-10 responses. To corroborate our findings, both intracellular and secreted levels of IFN-γ and IL-17 were measured and similar results were observed. CD4+T cells from arthritic mice showed increase surface expression of IL-22R1(13.3%) in comparison to naïve mice (1.50%) or mice from the initiation phase (1.97%). Flowcytometrically, IL-22R1 was detectable in CD19+ cells, however, the expression levels were similar in naïve mice, mice from initiation phase or arthritic mice .In-vitro, CD4T cells from arthritic mice when co-cultured with antigen presenting cells in the presence or absence of IL-22, suppressed or induced IFN-g respectively. In another in-vitro set up, CD19 cells from arthritic mice when cultured in the presence of recombinant IL-22, showed significant suppression of anti-collagen IgG1 and augmentation of IgG2a responses. These in vitro results are in agreement with our in vivo findings suggesting that IL-22R1 expression in T and B cells is functionally active and associated with IFN-g regulation in T cells or pathogenic anti-collagen IgG2a antibody production from B cells.  Our results shows that IL-22R1 may be induced on immunocytes during inflammatory state thus enabling them to respond to IL-22.

Conclusion:

Endogenous IL-22 suppresses Th1 responses and is pathogenic after onset of arthritis. IL-22R1 is upregulated in CD4 T cells during arthritis and regulates IFN-g in T cells.


Disclosure:

S. Justa,
None;

X. Zhou,
None;

S. Sarkar,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endogenous-il-22-regulates-th1-responses-and-plays-a-pathogenic-role-after-the-onset-of-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology